Genetic Pheochromocytoma -a Review

Authors

  • F. B. Pambinezhuth National Diabetes and Endocrine center –Royal hospital, Muscat Oman

Keywords:

Pheochromocytoma, paraganglioma ,germ line mutations ,familial syndromes.

Abstract

The prevalence of pheochromcytoma in hypertensive patients  is less than 1%.Most PHEOs  occur sporadically, but a substantial proportionmay be associated with germ line mutations of genes predisposing to thedevelopment of familial syndromes like multiple endocrineneoplasia(MEN),Von-Hippel Lindau(VHL) disease,neurofibromatosis type 1(NF-1),familial paraganglioma/pheochromocytoma (PGL/PHEO) related to geneticmutation encoding the mitochondrial protein succinate dehdrogenase sub units(SDH-BCD) .Screening for genetic mutation is imperative as it may add more onmanagement and surveillance of this patients .This review summarize therelevant data related to this  fascinating clinical entity.

References

Amar L, Bertherat et al 2005a Genetic testing pheochromocytoma or functional paraganglioma, Journal of clinical oncology 23 8812-8818

Baysal BE, Willett-Brozick et al 2002, prevalnec of SDHB, SDHC and SDHD germ line mutation in clinic patients with head and neck paraganglioma, Journal of medical genetics 39 178-183

Benn DE, Gimenz-Roqueplo AP et al 2006, Clinical presentation and presence of pheochromocytoma/paraganglioma syndrome. Journal of clinical endocrinology and metabolism 91 827-836

Brandi MLGagel RF et al 2001, Guideline for diagnosis and therapy of MEN type 1 and type 2JCEM 86 5638-5671

Brouwers FM,Eisenhofer G et al 2006,High frequency of SDHB mutations in patients with malignant catecholamine producing paraganglioma,JCEM 91 4505-4509

Choyke PL, Glenn GM et al 1995,von Hippel-Lindau disease, genetic ,clinical and imaging feature, Radiology 194 629-642

Gagel RF, Tashjian AH et al 1998,The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a,New England Journal of medicine 318 478-484

Gimenz-Roqueplo AP,lehnert H ,et al 2006,Pheochromocytoma, a new gene and screening strategies ,Clinical Endocrinology 65 699-705

Gutmann DH, Aylsworth A et al 1997, the diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and 2 Journal of American Medical Association 278 51-57

Hes FJ,, Hoppener JW et al, 2003 ,Pheochromocytoma in von Hippel-Lindau disease,JCEM 88 969-974

Koch CA, Pacak K et al 2002,The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors JCEM 87 5367-5384

Pacak K,, Eisenhofer G et al 2007,Pheochromocytoma recommendation for clinical practice from the first international symposium, Nature Clinical Practice. Endocrinology &Metabolism 3 92-102

Schiavi F, Bodeker Cc et al 2005, Predections and prevalence of paraganglioma syndrome associated with mutations of SDHC gene, Journal of American Medical association 294 2057-2063

Takashahi s,Nakai T et al 1989 effectiveness of long acting nifedipine in pheochromocytoma,Japanese Heart Journal 30 751-757

Vander Harst E,deHerder WW et al 2001,(123I )metaiodobezyl-guadine and( 111 In) octreotide uptake in benign and malignant pheochromocytoma JCEM 86 685-693.

Published

2013-11-30

How to Cite

B. Pambinezhuth, F. . (2013). Genetic Pheochromocytoma -a Review. Scientific Journal of Medical Science, 2(11), 208-211. Retrieved from http://sjournals.com/index.php/sjms/article/view/1309

Issue

Section

Review Article